Dissemination of Blandm-5 in Escherichia Coli via the Incx3 Plasmid From Different Regions in China

Xiaofeng Hu
Center for Disease Control and Prevention of PLA

Lang Yang
Center for Disease Control and Prevention of PLA

Nian Dong
Xingcheng special service recuperation center of PLA Strategic support force

Yanfeng Lin
Center for Disease Control and Prevention of PLA, Academy of Military Medical Sciences, Academy of Military Sciences

Ling Zhang
73 Army Hospital

Xu Wang
Center for Disease Control and Prevention in Northern Theater Command of PLA

Xudong Guo
Centers for Disease Control and Prevention of PLA

Ying Xiang
Centre for Disease Control and Prevention of PLA

Lianqun Jin
Center for Disease Control and Prevention of PLA

Chuanfu Zhang
Center for Disease Control and Prevention of PLA

Yansong Sun
State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology

Peng Li
Center for Disease Control and Prevention of PLA

Hongbin Song
Center for Disease Control and Prevention of PLA

Qiu Shaofu (qiushf0613@hotmail.com)
CDC: Centers for Disease Control and Prevention of PLA
Abstract

Background: Recently, the spread of NDM-5-producing *Escherichia coli* has become a severe challenge in clinical therapy, which necessitates reliable detection and surveillance methods. However, limited information is available regarding the prevalence and dissemination of the *bla*\textsubscript{NDM-5} gene in *Escherichia coli* in China. Therefore, we investigated the dissemination of the *bla*\textsubscript{NDM-5} gene in carbapenem-resistant *Escherichia coli* isolates from different regions in China.

Methods: A total of 1,180 carbapenem-resistant *enterobacteriaceae* strains were obtained from patients admitted to the 20 sentinel hospitals in eight cities. Strains positive for *bla*\textsubscript{NDM-5} were detected using the Vitek 2 compact system, 16S rRNA gene sequencing, PCR, the S1-pulsed-field gel electrophoresis assay, and Southern blot hybridization. The horizontal-transfer capability of the *bla*\textsubscript{NDM} gene was assessed by filter mating with a standard *E. coli* J53 azide-resistant strain as the recipient. Genotyping, susceptibility testing, and whole genome sequencing were performed.

Results: Seven strains of *bla*\textsubscript{NDM-5}-positive *E.coli* was detected in 1180 clinical strains from different regions in China. The *bla*\textsubscript{NDM-5}-carrying strains showed resistance to multiple tested antibiotics and belonged to two widespread sequence types, ST167 and ST405. Antimicrobial resistance genes including *bla*\textsubscript{CTX-M}, *bla*\textsubscript{OXA}, *bla*\textsubscript{CMY}, and two novel *bla*\textsubscript{TEM} variants (*bla*\textsubscript{TEM-230} and *bla*\textsubscript{TEM-231}) were also identified. Southern blotting located the *bla*\textsubscript{NDM-5} gene on 46-kb IncX3 plasmids in all isolates, which showed only two single nucleotide differences between EJN003 and the other strains.

Conclusions: This study further confirms the increasing occurrence of *bla*\textsubscript{NDM-5}-carrying IncX3 plasmids and the dissemination of carbapenem resistance in *E. coli* isolates via the plasmid from different parts in China, which warrants stringent surveillance and control measures.

1. Introduction

*Escherichia coli* is one of the most common causative agents of infection in humans, and the emergence of resistance to third-generation cephalosporins by[1] extended-spectrum beta-lactamases (ESBLs) has led to an increased use of carbapenem compounds. The growing incidence of resistance to carbapenems among *Enterobacteriaceae* is of major concern worldwide. Among the newly emerged lactamases, New Delhi metallo-lactamase (NDM) represents the latest threat for public health. Since NDM-1 was first reported in 2009 in a Swedish patient of Indian origin[2], NDM-producing bacteria have spread globally and have caused various types of clinical infections[3]. To date, 24 *bla*\textsubscript{NDM} gene variants have been described worldwide, and some variants confer elevated carbapenem resistance[4,5]. The rapid evolution and dissemination of NDMs represent a crucial challenge for clinical infection treatments, which necessitates reliable detection and surveillance method[6].

NDM-5, a variant with higher carbapenemase activity than NDM-1, was first identified in an *E. coli* strain isolated in 2011 from a patient in the UK with a recent history of hospitalization in India[4]. It has two
amino acid substitutions (Val88Leu and Met154Leu) relative to NDM-1, and confers increased resistance to extended-spectrum cephalosporins and carbapenems. Since then, NDM-5-producing strains have been identified in many areas including China. The widespread occurrence of NDM-5 in recent years highlights the need for international attention. Previous studies have reported the prevalence and dissemination of $bla_{NDM-5}$ among E.coli from different regions in China[7,8]. Herein, we further evaluated the potential transmission of $bla_{NDM-5}$-harboring E. coli from different regions in China in the current study. Whole genome analysis and molecular analysis were performed to provide a clear and solid molecular epidemiological description of NDM-5-producing E. coli.

2. Materials And Methods

2.1 Bacterial Strains, Detection of the NDM Gene, and Antimicrobial Susceptibility Testing

A total of 1,180 carbapenem-resistant enterobacteriaceae strains obtained from patients admitted to the 20 sentinel hospitals in eight cities from January 2014 to December 2015 in China were identified using the VITEK 2 system (BioMérieux, France). In a retrospective study, the presence of $bla_{NDM}$ was screened by PCR amplification and sequencing using primers described in our previous study[9]. Seven $bla_{NDM-5}$-positive E.coli strains were identified. The antimicrobial susceptibility testing was performed using the VITEK 2 system (BioMérieux). The minimal inhibitory concentration (MIC) results were interpreted according to the Clinical and Laboratory Standards Institute (CLSI) guidelines[10]. E. coli ATCC25922 was used for quality control. Collection of the clinical isolates was part of the routine surveillance of carbapenem-resistant Enterobacteriaceae. This study was approved by the institutional ethics committees of Academy of Military Medical Sciences.

2.2 S1- Pulsed-field gel electrophoresis (PFGE), Southern Blotting and Plasmid Conjugation

Genomic DNA from the seven strains was prepared in agarose plugs and digested with S1 nuclease (Takara, Dalian, China). Linearized plasmids and partially digested genomic DNA were separated using a CHEF-DR III system (Bio-Rad, Hercules, CA, USA). Southern blot analysis to locate the $bla_{NDM}$ genes was performed using specific digoxigenin-labeled probes (Roche)[11]. The NDM-1-producing Acinetobacter isolate 1750 reported by our laboratory[12] was used as a positive control, S. enterica H9812 was used as a reference size standard and a negative control.

The horizontal-transfer capability of the $bla_{NDM-5}$ gene was assessed by broth and filter mating using the seven strains as donors and a standard E. coli J53 azide-resistant strain as the recipient. The donor and recipient cultures were mixed in LB broth and incubated at 37°C for 24 hours. MacConkey agar containing 100 mg/liter sodium azide and 0.5 mg/liter meropenem was used to select E. coli J53
transconjugants[13]. Antimicrobial susceptibility testing and PCR amplification of the transconjugants were subsequently performed to confirm the transfer of the plasmid to the recipient.

### 2.3 Whole Genome Sequencing and Determination of Genetic Relatedness

Genomic DNA was extracted from seven *E. coli* isolates using the QIAamp DNA Mini Kit following the manufacturer’s protocol (Qiagen, Inc., Valencia, CA, USA). Whole genome sequencing was performed on the Illumina Hiseq 2500 platform with a 350-bp insert at the Beijing Novogene Technology Co., Ltd. Paired-end reads of 150 bp were assembled using SOAPdenovo (v2.04) with coverage ranging from 113- to 157-fold. Scaffolding and gap filling were performed using SSPACE[14] and GapFiller. The plasmid pNDM-QD28[15] was selected as a reference. Gaps were closed using reference-guided assembly and manually checked by re-mapping raw reads against the reference. Plasmid sequences were annotated using RAST. Plasmid replicon type was assigned using PlasmidFinder (*Enterobacteriaceae*)[16].

The STs of seven *E. coli* isolates were identified using the MLST web server[17]. PFGE was performed after *XbaI* digestion with reference to the standard PulseNet conditions. Restriction patterns were compared visually using BioNumerics software with the *Salmonella enterica* serovar Braenderup H9812 as a size marker. *E. coli* strain K-12_DH10B (GenBank accession number CP000948) was used as the reference for alignment. Single nucleotide polymorphisms (SNPs) were identified using BWA (v0.7.12)[18] and SAMtools (v1.3). The concatenated SNPs were aligned to construct a Maximum-Likelihood phylogenetic tree using RAxML (v8.2.4) with the GTR model and the gamma distribution[19]. Genome sequences of ten pNDM5-ESY001-like plasmids were also downloaded for phylogenetic analysis as described above.

### 3. Results

#### 3.1 Bacterial Strains and Antimicrobial Susceptibility Testing

Seven *bla<sub>NDM-5</sub>*-positive isolates were recovered from seven hospitalized patients from three sources in three different cities in China. EBJ001 and EBJ003 were isolated from Beijing, ESY001, ESY002, and ESY003 from Shenyang, EJN001 and EJN003 from Jinan. (Table 1). None of the patients had ever traveled abroad. All *E. coli* strains were resistant to carbapenems, cephalosporins, quinolones, aztreonam, ampicillin, and sulfamethoxazole/trimethoprim, and were mostly susceptible to amikacin (Table 2).

#### 3.2 Genetic Relatedness of all Strains
MLST analysis revealed that strain EBJ003 belonged to ST405, which fell into phylogenetic group D and was distinguishable from other strains by PFGE. The other six strains belonged to ST167 and phylogenetic group A (Fig. 1). ESY001 and ESY002 were classified into the same pulsotype, whereas EJN001, EJN003, ESY003, and EBJ001 were classified into different pulsotypes (Fig. 2), suggesting both clonal and non-clonal dissemination.

### 3.3 Virulence and Resistance Genes in All Strains

The seven strains harbored type II and III secretion systems. Certain virulence factors were exclusively observed in EBJ003, such as *fim* (encoding type I fimbriae regulatory proteins), *iuc* (encoding aerobactin siderophore biosynthesis proteins), and *irp* and *ybt* (encoding yersiniabactin biosynthetic proteins) genes.

In addition to *bla*<sub>NDM-5</sub>, other antimicrobial resistance genes were also frequently identified in the seven *E. coli* strains including *bla<sub>CTX-M</sub>*<sub>-</sub>*, bla<sub>TEM</sub>*<sub>-</sub>, *aac(3)-Ila*, *aada5*, *dfra7* and *mphA*. The coexistence of a *bla<sub>CTX-M-14</sub>* gene and a *bla<sub>CTX-M-55</sub>* gene was observed in EBJ003 (Table 1). A *bla<sub>CTX-M-24</sub>* gene was identified in EBJ001, and *bla<sub>CTX-M-55</sub>* was identified in EJN003, whereas other strains harbored a single *bla*<sub>CTX-M-14</sub>. Also, *bla<sub>CMY-42</sub>* was detected in EJN001 and EBJ001, and *bla<sub>OXA-1</sub>* was identified in EBJ003. Strain ESY001 harbored two *bla*<sub>TEM</sub> variants designated as *bla<sub>TEM-230</sub>* and *bla<sub>TEM-231</sub>*. The deduced protein sequence of *bla<sub>TEM-230</sub>* had a single amino acid substitution at position 233 (Ser→Thr) relative to its closest homolog TEM-168. The *bla<sub>TEM-230</sub>* gene was located on an IncX6 plasmid and inserted between the *TivB5* and *TivB6* genes related to type IV secretion systems. The *bla<sub>TEM-231</sub>* gene was located on an IncFIB plasmid and inserted between a Tn3 mobile element and *sul2*.

### 3.4 Characteristics of the *blaNDM-5*-Carrying Plasmids

In this study, all seven strains successfully transferred the *bla*<sub>NDM-5</sub> gene to the recipient with high frequency ranging from 6.56 × 10<sup>-3</sup> to 1.33 × 10<sup>-2</sup> per donor cell. The transfer of the *bla*<sub>NDM-5</sub> gene and carbapenem resistance to the transconjugants was confirmed by PCR amplification and antimicrobial susceptibility testing. S1-PFGE and subsequent Southern hybridization revealed that *bla*<sub>NDM-5</sub> was carried by plasmids of the same size (∼45 kb) (Fig.3)

Sequence analysis revealed that the *bla*<sub>NDM-5</sub>-carrying plasmid was identical in ESY001 (pNDM5-ESY001), ESY002 (pNDM5-ESY002), ESY003 (pNDM5-ESY003), EBJ001 (pNDM5-EBJ001), EBJ003 (pNDM5-EBJ003), and EJN001 (pNDM5-EJN001). pNDM5-ESY001 was 46,161 bp in length and had only two single nucleotide substitutions compared with the *bla*<sub>NDM-5</sub>-carrying plasmid pNDM5-EJN003 in EJN003, and the two single nucleotide substitutions were located within *VirB4* and the non-coding region, respectively. A BLASTn search against the NCBI database revealed that pNDM5-ESY001 shared 100% coverage and >99% identity with plasmid pNDM5-SSH006 from Shanghai, China[20]. A single nucleotide substitution located within a truncated *cutA1* gene downstream of *bla*<sub>NDM-5</sub> was identified. A variety of
blaNDM-5-harboring plasmids show high similarity with the plasmid pNDM5-ESY001 including pNDM_MGR194[21], pEc1929[22], pNDM-QD28, pNDM-QD29[15], pECNDM101, and pNDM5-IncX3[23]. The nucleotide differences among these plasmids were mostly located within insertion sequences and genes associated with type IV secretion systems, partition, and DNA distortion (Fig. 4). The plasmids pJEG027[24] carrying blaNDM-4 and pKpN01-NDM7[25] carrying blaNDM-7 were also highly identical with pNDM5-ESY001 except for the variation of blaNDM alleles.

All the above plasmids shared the same genetic context of the blaNDM-5 gene (ISSwi3000-ISAb125-IS5-blaNDM-5-ble-trpF-tat-ΔctuA1-IS26-ΔumuD) (Fig. 5). pNDM5_0215[26], which was isolated from Chengdu, China, had an insertion of IS5 into IS3000. Another blaNDM-5-harboring IncX3 plasmid, pP744T-NDM5[27], from China had a similar NDM genetic context except for the deletion of a segment of the truncated ISAba125, whereas pTK1044[28] from Japan had a shorter ISAba125 remnant of 73bp, suggesting a possible dissemination of blaNDM-5 via mobile elements. A recently identified fusion plasmid pBJ114T-190[29] comprising both IncFIB and IncX3 replicons from China lost the ISSwi and IS3000 upstream of the blaNDM-5 gene, suggesting the continuing variation of the blaNDM-5 genetic context.

4. Discussion

NDM-5-producing Enterobacteriaceae show increased resistance to extended-spectrum cephalosporins and carbapenems, posing a significant threat to public health throughout the world. The coexistence of blaNDM-5 and other resistance genes confers multidrug resistance to pathogens, which is a serious problem for clinical treatment. This study identified seven NDM-5-producing E. coli isolates from three different cities in China.

Six of the seven strains belong to the ST167 type, which is an internationally disseminated clone of the ST10 complex. ST167 E. coli strains carry blaNDM-1, blaNDM-5[26], blaNDM-7[30], and a variety of blaCTX-M genes[26,31] in various countries. ST167 is the most prevalent blaNDM-bearing ST in China, accounting for 42% of NDM-producing E. coli isolates according to the nationwide surveillance[32]. Recent study reported several cases of clinical infection related to blaNDM-5-positive E. coli ST167 in Shanghai or Zhejiang China[33,34]. Strain EBJ003 belongs to ST405 and a different phylogenetic group D, suggesting distinct clonal dissemination from others. ST405 is a high-risk clone found in diverse hosts and it carries the blaNDM and blaCTX-M genes[35]. The blaNDM-5-positive strains in this study were associated with ESBL/AmpC genes or CTX-M-types, demonstrating their ability to acquire different resistance genes. Considering that ST167 and ST405 are both widely disseminated in China, further spread of multidrug-resistant E. coli could become a crucial issue in the clinical setting. In addition, an increasing number of virulence factors were identified in ST405 strain EBJ003 compared with ST167 strains, underscoring the potential danger of ST405 as an epidemic pathogen.

The nucleotide sequences of the blaNDM-5-carrying plasmids pNDM5-ESY001 and pNDM5-EJN003 were nearly identical to those of other IncX3 plasmids from China, suggesting that the pNDM5-ESY001-like
plasmid is an important reservoir and plays a critical role in the dissemination of blaNDM-5 in China. The pNDM5-ESY001-like plasmid (pNDM_MGR194) was first reported in Klebsiella pneumoniae in India and later in Australia[36] and Denmark. The blaNDM-5 carriers from Australia and Denmark were isolated from patients who had travelled to India, suggesting the linkage to Indian blaNDM-5 dissemination. The blaNDM-5 carriers isolated from China showed little association with the Indian subcontinent. However, considering that international travel is common and transmission routes between people are often unrecognized, the origin of the prevalence of pNDM5-ESY001-like plasmids in China remains unclear. IncX-type plasmids were earlier believed to have a narrow host range but were recently found to be prevalent in various members of Enterobacteriaceae. We previously reported the presence of an IncX3 plasmid similar to pNDM5-ESY001 in S. enterica[20]. The identification of pNDM5-ESY001-like plasmids in K. pneumoniae, S. enterica, and E. coli of different STs demonstrates their ability to mediate intra- and inter-species transfer of blaNDM-5, which would facilitate the wide distribution of NDM-5 across diverse enterobacterial species. Further surveillance should be devoted to monitoring the transfer of such blaNDM-5-carrying IncX3 plasmids among Enterobacteriaceae.

Phylogenetic analysis of plasmids revealed that the blaNDM-4-carrying plasmid pJEG027[24] in Australia and the blaNDM-7-carrying plasmid pKpN01-NDM7[25] in Canada are indistinguishable from the pNDM5-ESY001-like plasmids. Because blaNDM-5 and blaNDM-7 have a single nucleotide substitution relative to blaNDM-4 (G388A and G262T, respectively), pNDM5-ESY001 and pKpN01-NDM7 are likely to have arisen from a pJEG027-like plasmid through acquisition of different variations.

In conclusion, we report seven drug-resistant E. coli isolates harboring blaNDM-5 and multiple ESBL/AmpC genes from patients in different geographic locations in China. The coexistence of resistance to antimicrobials of different groups in clinical NDM-5-producing E. coli isolates is a serious concern. These isolates belonged to ST167 and ST405 and contained a transferable plasmid, pNDM5-ESY001 (pNDM5-EJN003), which serves as an important reservoir for the dissemination of blaNDM-5. The present findings underscore the threat of NDM-5 carbapenemase circulation via IncX3 plasmids and the urgency of implementing stringent surveillance and control measures.

**Nucleotide sequence accession number**

The shotgun whole genome sequences of strains ESY001, ESY002, ESY003, EJN001, EJN003, EBJ001 and EBJ003 have been deposited in NCBI GenBank under accession numbers PUJM0000000 to PUJS0000000.

**Declarations**

**Ethics approval and consent to participate:** Not applicable.

**Consent for publication:** Not applicable.
Availability of data and material: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests: The authors declare that they have no competing interests

Funding: This work was supported by the National Key R&D Program of China (No. 2018YFC1603801 and 2018YFC1200104), the National Natural Science Foundation of China (No. 82003519 and 81872678), and the Medical Technology Youth Development Programme (No. 21QNPY126).

Authors' contributions: X.-F.H wrote the main manuscript and fully participated in all experiments. L.Y contributed to the bioinformatics data analysis. S.-F.Q designed the study. N.D and Y.-F.L participated in data collection. L.Z and X.W participated in the specimen collection. X.-D.G, Y.X, L.-Q.J and C.-F.Z participated in all experiments. H.-B.S, Y.-S.S and P.L gave final approval of the version to be submitted. All authors made substantial contributions to preparation and submission of manuscript.

Acknowledgements: We are particularly grateful to Dr. Mingliang Chen (Department of Chemical Defense Medicine, School of Military Preventive Medicine, Third Military Medical University) for his critical review and valuable suggestions that greatly improved the quality of this manuscript.

References

1. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev. 2005;18:306–25.
2. Cornaglia G, Giamarellou H, Rossolini GM. Metallo-β-lactamases: a last frontier for β-lactams? Lancet Infect Dis. 2011;11:381–93.
3. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009;53:5046–54.
4. Liu L, Feng Y, McNally A, Zong Z. blaNDM-21, a new variant of blaNDM in an Escherichia coli clinical isolate carrying blaCTX-M-55 and rmtB. J Antimicrob Chemother. 2018;73:2336–9.
5. Wu W, Feng Y, Tang G, Qiao F, McNally A, Zong Z. NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings. Clin Microbiol Rev. 2019;32.
6. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10:597–602.
7. Sun P, Xia W, Liu G, Huang X, Tang C, Liu C, et al. Characterization Of blaNDM-5-Positive Escherichia coli Prevalent In A University Hospital In Eastern China. Infect Drug Resist. 2019;12:3029–38.
8. Zou H, Jia X, Liu H, Li S, Wu X, Huang S. Emergence of NDM-5-Producing Escherichia coli in a Teaching Hospital in Chongqing, China: IncF-Type Plasmids May Contribute to the Prevalence of
9. Hu X, Xu X, Wang X, Xue W, Zhou H, Zhang L, et al. Diversity of New Delhi metallo-beta-lactamase-producing bacteria in China. Int J Infect Dis. 2017;55:92–5.

10. Wayne, PA. Performance standards for antimicrobial susceptibility testing: twenty-third informational supplement. M100-S23. Performance standards for antimicrobial susceptibility testing: twenty-third informational supplement M100-S23. Clinical and Laboratory Standards Institute; 2013.

11. Borgia S, Lastovetska O, Richardson D, Eshaghi A, Xiong J, Chung C, et al. Outbreak of carbapenem-resistant enterobacteriaceae containing blaNDM-1, Ontario, Canada. Clin Infect Dis. 2012;55:e109-117.

12. Wang X, Liu W, Zou D, Li X, Wei X, Shang W, et al. High rate of New Delhi metallo-β-lactamase 1-producing bacterial infection in China. Clin Infect Dis. 2013;56:161–2.

13. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis. 2011;11:355–62.

14. Boetzer M, Henkel CV, Jansen HJ, Butler D, Pirovano W. Scaffolding pre-assembled contigs using SSPACE. Bioinformatics. 2011;27:578–9.

15. Zhu Y-Q, Zhao J-Y, Xu C, Zhao H, Jia N, Li Y-N. Identification of an NDM-5-producing Escherichia coli Sequence Type 167 in a Neonatal Patient in China. Sci Rep. 2016;6:29934.

16. Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, Lund O, Villa L, et al. In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. Antimicrob Agents Chemother. 2014;58:3895–903.

17. Larsen MV, Cosentino S, Rasmussen S, Friis C, Hasman H, Marvig RL, et al. Multilocus sequence typing of total-genome-sequenced bacteria. J Clin Microbiol. 2012;50:1355–61.

18. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26:589–95.

19. Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics. 2014;30:1312–3.

20. Yang L, Hu X, Xu X, Yang C, Xie J, Hao R, et al. Salmonella enterica serovar Typhimurium ST34 co-expressing blaNDM-5 and blaCTX-M-55 isolated in China. Emerg Microbes Infect. 2017;6:e61.

21. Krishnaraju M, Kamatchi C, Jha AK, Devasena N, Vennila R, Sumanthi G, et al. Complete sequencing of an IncX3 plasmid carrying blaNDM-5 allele reveals an early stage in the dissemination of the blaNDM gene. Indian J Med Microbiol. 2015;33:30–8.

22. Chen D, Gong L, Walsh TR, Lan R, Wang T, Zhang J, et al. Infection by and dissemination of NDM-5-producing Escherichia coli in China. J Antimicrob Chemother. 2016;71:563–5.

23. Li A, Yang Y, Miao M, Chavda KD, Mediavilla JR, Xie X, et al. Complete Sequences of mcr-1-Harboring Plasmids from Extended-Spectrum-β-Lactamase- and Carbapenemase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2016;60:4351–4.
24. Espedido BA, Dimitrijovski B, van Hal SJ, Jensen SO. The use of whole-genome sequencing for molecular epidemiology and antimicrobial surveillance: identifying the role of IncX3 plasmids and the spread of blaNDM-4-like genes in the Enterobacteriaceae. J Clin Pathol. 2015;68:835–8.

25. Chen L, Peirano G, Lynch T, Chavda KD, Gregson DB, Church DL, et al. Molecular Characterization by Using Next-Generation Sequencing of Plasmids Containing blaNDM-7 in Enterobacteriaceae from Calgary, Canada. Antimicrob Agents Chemother. 2015;60:1258–63.

26. Yang P, Xie Y, Feng P, Zong Z. blaNDM-5 carried by an IncX3 plasmid in Escherichia coli sequence type 167. Antimicrob Agents Chemother. 2014;58:7548–52.

27. Ho P-L, Wang Y, Liu MC-J, Lai EL-Y, Law PY-T, Cao H, et al. IncX3 Epidemic Plasmid Carrying blaNDM-5 in Escherichia coli from Swine in Multiple Geographic Areas in China. Antimicrob Agents Chemother. 2018;62.

28. Nakano R, Nakano A, Hikosaka K, Kawakami S, Matsunaga N, Asahara M, et al. First report of metallo-β-lactamase NDM-5-producing Escherichia coli in Japan. Antimicrob Agents Chemother. 2014;58:7611–2.

29. Xie M, Li R, Liu Z, Chan EWC, Chen S. Recombination of plasmids in a carbapenem-resistant NDM-5-producing clinical Escherichia coli isolate. J Antimicrob Chemother. 2018;73:1230–4.

30. Cuzon G, Bonnin RA, Nordmann P. First identification of novel NDM carbapenemase, NDM-7, in Escherichia coli in France. PLoS ONE. 2013;8:e61322.

31. Ramos PIP, Picão RC, Almeida LGP de, Lima NCB, Girardello R, Vivan ACP, et al. Comparative analysis of the complete genome of KPC-2-producing Klebsiella pneumoniae Kp13 reveals remarkable genome plasticity and a wide repertoire of virulence and resistance mechanisms. BMC Genomics. 2014;15:54.

32. Zhang R, Liu L, Zhou H, Chan EW, Li J, Fang Y, et al. Nationwide Surveillance of Clinical Carbapenem-resistant Enterobacteriaceae (CRE) Strains in China. EBioMedicine. 2017;19:98–106.

33. Li X, Fu Y, Shen M, Huang D, Du X, Hu Q, et al. Dissemination of blaNDM-5 gene via an IncX3-type plasmid among non-clonal Escherichia coli in China. Antimicrob Resist Infect Control. 2018;7:59.

34. Zhang F, Xie L, Wang X, Han L, Guo X, Ni Y, et al. Further Spread of bla NDM-5 in Enterobacteriaceae via IncX3 Plasmids in Shanghai, China. Front Microbiol. 2016;7:424.

35. Dagher C, Salloum T, Alousi S, Arabaghian H, Araj GF, Tokajian S. Molecular characterization of Carbapenem resistant Escherichia coli recovered from a tertiary hospital in Lebanon. PLoS ONE. 2018;13:e0203323.

36. Wailan AM, Paterson DL, Caffery M, Sowden D, Sidjabat HE. Draft Genome Sequence of NDM-5-Producing Escherichia coli Sequence Type 648 and Genetic Context of blaNDM-5 in Australia. Genome Announc. 2015;3.

**Tables**

**Table 1.** Patient demographics, molecular features and bla resistance genes of 7 E. coli strains
| Strain  | Year | Region   | Source  | MLST | bla genes carried                  |
|---------|------|----------|---------|------|-----------------------------------|
| ESY001  | 2014 | Shenyang | blood   | ST167| \(\text{bla}_{\text{NDM-5}}, \text{bla}_{\text{CTX-M-14}}, \text{bla}_{\text{TEM-230}}, \text{bla}_{\text{TEM-231}}\) |
| ESY002  | 2014 | Shenyang | blood   | ST167| \(\text{bla}_{\text{NDM-5}}, \text{bla}_{\text{CTX-M-14}}, \text{bla}_{\text{TEM-230}}\) |
| ESY003  | 2014 | Shenyang | sputum  | ST167| \(\text{bla}_{\text{NDM-5}}, \text{bla}_{\text{CTX-M-14}}, \text{bla}_{\text{TEM-135}}\) |
| EJN001  | 2014 | Jinan    | urine   | ST167| \(\text{bla}_{\text{NDM-5}}, \text{bla}_{\text{CTX-M-14}}, \text{bla}_{\text{CMY-42}}\) |
| EJN003  | 2014 | Jinan    | blood   | ST167| \(\text{bla}_{\text{NDM-5}}, \text{bla}_{\text{CTX-M-55}}\) |
| EBJ001  | 2014 | Beijing  | urine   | ST167| \(\text{bla}_{\text{NDM-5}}, \text{bla}_{\text{CTX-M-24}}, \text{bla}_{\text{CMY-42}}\) |
| EBJ003  | 2014 | Beijing  | urine   | ST405| \(\text{bla}_{\text{NDM-5}}, \text{bla}_{\text{CTX-M-14}}, \text{bla}_{\text{CTX-M-55}}, \text{bla}_{\text{OXA-1}}\) |

**TABLE 2. Antibiotic susceptibilities of seven *E. coli* strains and their J53 transconjugants**
| Antimicrobial                        | MIC (µg/ml) |
|-------------------------------------|-------------|
|                                     | ESY001 [J53] | ESY002 [J53] | ESY003 [J53] | EBJ001 [J53] | EBJ003 [J53] | EJN001 [J53] | EJN003 [J53] |
| Ampicillin                          | ≥32 [≥32]   | ≥32 [≥32]   | ≥32 [≥32]   | ≥32 [≥32]   | ≥32 [≥32]   | ≥32 [≥32]   | ≥32 [≥32]   |
| Amoxicillin-clavulanic acid         | ≥32 [≥32]   | ≥32 [≥32]   | ≥32 [≥32]   | ≥32 [≥32]   | ≥32 [≥32]   | ≥32 [≥32]   | ≥32 [≥32]   |
| Piperacillin                         | ≥128 [≥128] | ≥128 [≥32]  | ≥128 [≥32]  | ≥128 [≥32]  | ≥128 [≥32]  | ≥128 [≥128] | ≥128 [≥128] |
| Cefazolin                           | ≥64 [≥64]   | ≥64 [≥64]   | ≥64 [≥64]   | ≥64 [≥64]   | ≥64 [≥64]   | ≥64 [≥64]   | ≥64 [≥64]   |
| Ceftazidime                         | ≥64 [≥64]   | ≥64 [≥64]   | ≥64 [≥64]   | ≥64 [≥64]   | ≥64 [≥64]   | ≥64 [≥64]   | ≥64 [≥64]   |
| Ceftriaxone                         | ≥64 [≥64]   | ≥64 [≥64]   | ≥64 [≥64]   | ≥64 [≥64]   | ≥64 [≥64]   | ≥64 [≥64]   | ≥64 [≥64]   |
| Cefepime                            | ≥64 [8]     | ≥64 [8]     | ≥64 [8]     | ≥64 [8]     | ≥64 [8]     | ≥64 [8]     | ≥64 [8]     |
| Aztreonam                           | ≥64 [≤1]    | ≥64 [≤1]    | ≥64 [≤1]    | ≥64 [≤1]    | ≥64 [≤1]    | ≥64 [≤1]    | ≥64 [≤1]    |
| Imipenem                            | ≥16 [8]     | ≥16 [8]     | ≥16 [8]     | ≥16 [8]     | ≥16 [4]     | ≥16 [≥16]   | ≥16 [≥16]   |
| Meropenem                           | ≥4 [2]      | ≥4 [2]      | ≥4 [2]      | ≥4 [2]      | ≥16 [2]     | ≤16 [1]     | ≥16 [1]     |
| Amikacin                            | ≤2 [≤2]     | ≤2 [≤2]     | ≤2 [≤2]     | ≤2 [≤2]     | 32 [≤2]     | ≥64 [≤2]    | ≥64 [≤2]    |
| Gentamicin                          | ≥16 [≤1]    | ≤1 [≤1]     | ≥16 [≤1]    | ≥16 [2]     | ≥16 [≤1]    | ≥16 [≤1]    | ≥16 [≤1]    |
| Ciprofloxacin                       | ≥4 [≤0.25]  | ≥4 [≤0.25]  | ≥4 [≤0.25]  | ≥4 [≤0.25]  | ≥4 [≤0.25]  | ≥4 [≤0.25]  | ≥4 [≤0.25]  |
| Levofloxacin                        | ≥8 [≤0.25]  | ≥8 [≤0.25]  | ≥8 [≤0.25]  | ≥8 [≤0.25]  | ≥8 [≤0.25]  | ≥8 [≤0.25]  | ≥8 [≤0.25]  |
| Tetracycline                        | ≥16 [≤1]    | ≥16 [2]     | ≥16 [2]     | ≥16 [≤1]    | ≥16 [2]     | 4 [2]       | ≥16 [2]     |
| Nitrofurantoin                      | 64 [≤16]    | 64 [≤16]    | 64 [≤16]    | 64 [≤16]    | 32 [≤16]    | 128 [≤16]   | ≤16 [≤16]   |
| Sulfamethoxazole-trimethoprim       | ≥320 [≤20]  | ≥320 [≤20]  | ≥320 [≤20]  | ≥320 [≤20]  | ≥320 [≤20]  | ≥320 [≤20]  | ≥320 [≤20]  |

*The antibiotic susceptibilities of transconjugants are indicated in square brackets.*